TSTatyana V. Shamanskaya

Tatyana V. Shamanskaya

*This is an algorithmically generated author record based on publicly available information.

Tatyana V. Shamanskaya has a total of 284 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Multiparametric model of noninvasive diagnosis of neuroblastoma in children based on a novel liquid biopsy marker C18 GD2 and serum tumor markers

    by Nikolay S. Ivanov, M. Ya. Yadgarov, D. Yu. Kachanov, S. S. Larin, M. D. Mollaev, E. A. Litvin, M. A. Maschan, N. S. Grachev, T. V. Shamanskaya

    Background. Neuroblastoma (NB) is one of the most common malignant solid tumors in childhood, in some cases presenting challenges for differential diagnosis at initial presentation. Serum tumor markers – neuron-specific enolase (NSE) and lactate dehydrogenase (LDH) – have limited diagnostic accuracy. Circulating C18 lipoform of GD2 may represent a promising liquid biopsy marker for NB, however, multiparametric diagnostic models combining GD2 with serum markers remain largely unexplored. Objective – to develop and internally validate a logistic regression model for noninvasive diagnosis of NB in children based on the combination of serum C18 lipoform GD2, NSE, and LDH levels, and to assess whether a neural network model (multilayer perceptron) improves diagnostic performance compared to logistic regression. Materials and methods. Serum concentrations of C18 lipoform GD2 were measured using a validated high-performance liquid chromatography-tandem mass spectrometry method, NSE and LDH were determined by standard techniques in primary patients with suspected neurogenic tumor between July 2021 and March 2024 (32 months) at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Missing NSE and LDH data were handled by multiple imputation (m = 20). A logistic model with three continuous predictors (GD2, NSE, LDH) was fitted in each imputed dataset, and coefficients were pooled using Rubin's rules. As an alternative, a neural network model (3 inputs, one hidden layer with 2 neurons, logistic output) was trained on the 6th imputation and applied to all 20 datasets. Model performance was assessed by AUC (95% confidence interval (CI)), as well as sensitivity, specificity, positive predictive value and negative predictive value for the logistic and neural network decision rules on the pooled multiply imputed dataset at the probability threshold determined by the Youden index. Internal validation was performed using strict 5-fold cross-validation on each imputed dataset. Differences in AUC between the two decision rules were assessed using DeLong's test. Results. This prospective single-center diagnostic cohort study included 155 patients aged 0–18 years with clinical and instrumental suspicion of a neurogenic tumor prior to specific therapy (89 with NB, 66 controls). The logistic model demonstrated an AUC of 0.842 (95% CI 0.829–0.856); only C18 lipoform GD2 remained a significant predictor (OR 1.07 per 1 nM; 95% CI 1.04–1.11; p 0.001). The mean AUC under strict 5-fold cross-validation was 0.838 (range – 0.812–0.867). The neural network decision rule showed a similar AUC on pooled data (0.841; 95% CI 0.828–0.855) but a lower and more variable mean AUC under cross-validation (0.759; range – 0.684–0.841). DeLong's test revealed no statistically significant difference between the AUCs of the logistic and neural network models (p = 0.904). Conclusion. Circulating C18 lipoform GD2 may serve as a key component of the diagnostic model in patients with suspected neurogenic tumor, while NSE and LDH contribute minimal additional value. The neural network model does not provide a significant AUC advantage and is less stable than logistic regression. Given the comparable discriminatory ability, greater robustness, and interpretability, the logistic regression model was selected as the final decision rule for noninvasive NB diagnosis and implemented as an online risk calculator.

  • Open Access

    Rare diseases as a global priority: the CIS Orphan Forum and the path toward collaboration with BRICS

    by Nuriya Z. Musina, Ahmed Al Saidi, Ayman W. El-Hattab, Helen Malherbe, Prasanna Kumar B. Shirol, Ulrike Schwerdtfeger, Dilorom I. Akhmedova, Tamara U. Aripova, Bakhyt M. M. Baigaliyeva, Zaure D. Dushimova, et al.

    The Second Orphan Forum of the Commonwealth of Independent States, held in Moscow on June 26–27, 2025, served as a platform to translate World Health Assembly Resolution 78.11 on rare diseases into coordinated policy action. The Forum convened delegates from eight Commonwealth of Independent States members and representatives from India, the United Arab Emirates, South Africa, and Oman, advancing interregional cooperation. Participants highlighted shared challenges: lack of national strategies and harmonized definitions of rare diseases, gaps in diagnostics and care infrastructure, limited registries, shortages of trained specialists, and unstable funding. The adopted Resolution set four priority domains for joint work: policy and regulatory development; organization of care and workforce capacity; pharmaceutical provision and health technology assessment; and international collaboration. Country presentations showed progress alongside persistent gaps. Priorities include expanding screening, establishing centers of expertise, improving patient pathways, extending reimbursement, introducing accelerated regulatory procedures, and updating clinical guidelines. Recommendations emphasize integrated care, continuity from pediatric to adult services, stronger health technology assessment for orphan medicines, real-world data collection, and managed entry and risksharing agreements. The Forum also concluded that closer cooperation on rare diseases is needed within BRICS, especially to improve the efficiency of orphan medicine development, manufacturing, and procurement through coordinated approaches, demand aggregation, and joint price negotiations.

  • Open Access

    Eosinophilia and allergic reactions during immunotherapy with dinutuximab beta in patients with neuroblastoma

    by Anna V. Bykova, N. A. Andreeva, R. S. Oganesyan, I. V. Sidorov, N. S. Ivanov, D. T. Utalieva, M. V. Teleshova, O. S. Zatsarinnaya, L. A. Smirnova, R. A. Moiseenko, et al.

    Introduction. Over the past two decades, immunotherapy has become the standard of treatment for some solid malignancies in children including neuroblastoma (NB). It is a relatively safe treatment modality if appropriate supportive care is provided. However, like other treatments, immunotherapy can result in a unique toxicity profile that requires timely interpretation and appropriate management. One of the described side effects is eosinophilia that in some cases can be accompanied by adverse events affecting various organs and systems. Mechanisms of injury, critical target organs, and approaches to management are still understudied. Aim – to study the relationship between increased peripheral blood eosinophil counts and adverse events including clinical symptoms of acute tonsillitis developing during immunotherapy with dinutuximab beta in patients with NB. Being a retrospective analysis, this study did not require approval from the local Ethics Committee. Materials and methods. We retrospectively analyzed the medical history and clinical and laboratory data of 40 patients with NB who had undergone immunotherapy with dinutuximab beta as first- or second-line treatment at the Dmitry Rogachev National Medical Research Center from 2019 to 2023. Results. Eosinophilia was seen to develop between immunotherapy cycles and was accompanied by skin reactions in 47.5% of cases (in 19/40 patients) and by itchiness (14/40), bronchial obstruction syndrome (14/40) or acute tonsillitis (14/40) – in 35% of cases. From сycle to cycle, there was a tendency towards a decrease in maximum absolute eosinophil count as well as in the incidence of itchiness. At the same time, skin reactions and acute tonsillitis developed almost as frequently in the following cycles. A comparison of clinical symptoms with laboratory data revealed that eosinophilia was significantly correlated only with acute tonsillitis (p 0.05). In this study, we investigated potential causes of this condition. We reported a clinical case of acute tonsillitis that had developed during immunotherapy with dinutuximab beta confirming the hypothesis about the potential infiltration of the tonsils by eosinophils. Conclusions. One of the side effects of immunotherapy with dinutuximab beta in NB patients is non-infectious tonsillitis which can be confirmed by a histological analysis showing morphological features of eosinophilic infiltration of the palatine tonsils. A differential diagnosis between this condition and infections as well as careful monitoring of patients treated with dinutuximab beta is required for timely identification and correct interpretation of adverse reactions.

  • Open Access

    Targeted DNA Sequencing for Tailored Therapies in Children with Extracranial Solid Tumors

    by Nataliya A. Andreeva, Tatyana V. Shamanskaya, Denis Y. Kachanov, Nikolay V. Zhukov, Nina V. Gegeliya, Ruslan H. Abasov, Natalia Y. Usman, Anastasia V. Protsvetkina, Dmitry M. Konovalov, Dmitry V. Litvinov, et al.

    Next-generation sequencing (NGS) is instrumental for clinical decisions on molecularly targeted therapy (TT). In pediatric oncology, TT is a relatively rare choice administered chiefly on a tumor-agnostic basis. The investigation enrolled 304 pediatric patients with extracranial solid tumors that were diagnosed and treated in 2018–2023. Tumor DNA was sequenced using a customized QiaSeq panel (Qiagen, Hilden, Germany) of genes known to be relevant for pediatric solid tumors, including ALK, BRAF, BRCA1/2, EGFR, FGFR1, KIT, MAP2K1/2, NF1, PDGFRA/B, PIK3CA, PTEN, PTPN11, RAS family genes, etc. The assay allowed detection of nucleotide substitutions and small insertions/deletions, as well as gene copy number alterations. TT sensitivity predictors were identified in 120/304 cases (39.5%): Tier II in 83 patients, Tier IB in 32 patients (almost always ALK in neuroblastoma, n = 31) and Tier IA in 5 patients: BRAF p.V600E (n = 3) and NF1 aberrations (n = 2). TT commenced in 21/304 cases (6.9%), often first-line or as a first relapse therapy (14/21 cases), combined with chemotherapy (TT-CT) in 13 cases. The median of TT duration was 10.9 (range 0.8–43.5) months for single-mode and 12.3 (0.3–61.5) months for TT-CT. Clinical benefit rate was achieved in 14/21 patients (66.7%). At the time of writing, nine patients (42.8%) have no progression and are still on treatment for 30.4 months (range 10.3–40.5) after the start of TT. The median time to the best response to TT was 6 (range 0.8–12.3) months. The tolerance was generally good: the therapy was discontinued for toxicity in only one case. The study provides a TT-focused prospective analysis still rare in pediatric oncology. The outcomes indicate satisfactory tolerance and promising efficacy of TT, prompting an update of current treatment standards for several pediatric cancers.


  • Open Access

    Results of treatment of patients with posterior mediastinal neuroblastoma in the observation group

    by T. V. Shamanskaya, D. D. Kisurina, O. I. Bydanov, I. G. Khamin, D. M. Konovalov, V. Yu. Roshchin, N. A. Andreeva, G. V. Tereshchenko, A. P. Shcherbakov, Yu. N. Likar, et al.

    Background . Neuroblastoma (NB) with primary tumor located in the posterior mediastinum is a unique subgroup characterized by a higher incidence of life-threatening complications, such as epidural compression (EC) and respiratory failure, yet it is associated with favorable long-term outcomes. Materials and methods . The study included patients with low-risk posterior mediastinal NB treated at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology between January 2012 and September 2024 (152 months). Patients were stratified into risk groups and managed according to the GPOH-NB2004 protocol. We evaluated relapse/progression detection methods, disease characteristics, treatment approaches, and long-term outcomes. Results . The study included 146 patients with NB with primary tumor located in the posterior mediastinum, which is 21.6 % of all patients in the observation (low-risk) group registered in the research database of Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. The median age at diagnosis was 19.6 months (range 0.5–132.5 months) with a female predominance (male-to-female ratio 1:1.2). Most patients (85/146; 58.2 %) presented with stage 2 disease. 38/146 (26.0 %) patients received chemotherapy due to life threatening symptoms, primarily EC, while 87/146 (59.6 %) patients underwent best surgery in the volume of a macroscopic residual tumor. Relapse/progression occurred in 16.4 % (24/146), predominantly detected during routine follow-up imaging (18/24; 75,0 %), with a median time to relapse of 7.8 months (range 3.0–25.3 months). The majority of relapses/progressions were local (18/24; 75.0 %). In 93 % (14/15) of relapsed/progressed cases analyzed retrospectively, MLPA revealed segmental chromosomal aberrations (median 3 aberrations/ patient; range 0–6). The most frequent alterations included 17q gain (n = 11), 2p gain (n = 8), and deletions in 3p (n = 6), 11q (n = 5), and 4q (n = 4). The 5-year event-free survival in patients with mediastinal NB was 79,1 ± 4,0 %, patients with stage 1 showing the highest survival rates (90 ± 6 %) (p = 0.1932). The 5-year overall survival was 95,0 ± 2,1 %. The cumulative incidence of relapse/progression was 18.7 ± 3.5 %, while treatment-related mortality was 2.8 ± 1.4 % (one death from disease progression; five from therapy toxicity). Conclusions. Mediastinal NB is a prognostically favorable group, with excellent survival rates independent of age or stage. Most patients in the low-risk group achieved favorable outcomes, even after relapse/progression. For the majority of patients in the low-risk group, surgery only is sufficient, and this strategy allows to reduce the risk of mortality from the toxicity of therapy without reducing overall survival. However, chemotherapy remains critical for patients with life-threatening complications, such as EC and respiratory failure, which once again highlighting the challenges in managing this subgroup. Strict adherence to the entire follow-up plan during the period of catamnesis is essential for early relapse detection. The molecular profile of the tumor may predict relapses and treatment response, which underscores the need to integrate molecular diagnostic methods (MLPA) to all patients with NB in the low-risk group into routine diagnostics.

  • Open Access

    RET-rearranged spindle cell soft tissue sarcoma in children: description of a clinical case and literature review

    by O. S. Zatsarinnaya, A. E. Druy, D. M. Konovalov, N. A. Andreeva, A. V. Panferova, A. S. Sharlai, K. Yu. Sinichenkova, T. V. Shamanskaya, V. Yu. Roshchin, A. P. Shcherbakov, et al.

    Soft tissue sarcomas (SMTs) represent a heterogeneous group of malignant tumors of mesenchymal origin. The widespread introduction of next-generation sequencing techniques, including RNA sequencing, into clinical practice has led to the description of a variety of SMTs with rearrangements of genes encoding various kinases. The present article describes the clinical case of a 3-year-old patient with a low-grade spindle cell sarcoma with a detectable MYH10::RET RNA transcript. The literature review describes the role of the RET gene in the pathogenesis of malignant neoplasms, with emphasis on soft tissue tumors, and presents the clinical, molecular and genetic characteristics of pediatric cases of SMT with RET gene rearrangements and the results of their therapy. The role of various molecular oncology techniques in the identification of kinase gene rearrangements, including RET, is discussed.

  • Open Access

    Isolated leptomeningeal relapses in high-risk neuroblastoma

    by A. N. Turchina, D. Yu. Kachanov, N. A. Andreeva, D. T. Utalieva, R. A. Moiseenko, I. V. Sidorov, D. M. Konovalov, M. E. Dubrovina, A. A. Gvozdev, T. V. Shamanskaya

    Background. Neuroblastoma (NB) is the most common extracranial solid malignant tumor of childhood, about 50 % of patients with NB are stratified into a high-risk (HR) group at the time of diagnosis. Despite the multimodal approach to therapy, half of the patients develop relapse of the disease, affecting mostly bones and bone marrow. Relapses with localization in the central nervous system (CNS) are extremely rare and are predominantly parenchymal in nature. Isolated leptomeningial involvement at relapse is an incredibly rare (0.6 % of all relapses), but is characterized by extremely aggressive manifestation and associated with unfavorable prognosis.Materials and methods. A description of three clinical cases of CNS relapses with isolated leptomeningeal lesions in patients with HR NB treated at Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia.Results. The study included 3 patients with isolated leptomeningeal relapse of NB. The age at the time of the initial diagnosis was 23, 36, and 80 months. Initially, the patients were stratified into a HR group according to the GPOH NB-2004 protocol. Amplification in the MYCN gene was detected in two patients, gain MYCN in one; deletion of the 1p chromosomal region was also detected in two patients, and deletion of the 11q chromosomal region in one patient. Two patients had a mutation in the ALK gene: in one case, the mutation was found in the primary tumor tissue, in the other – in the relapse tumor tissue. The time from the initial diagnosis to the detection of leptomeningeal recurrence of the disease was 5, 15 and 16 months. In two cases, CNS relapse debuted with the appearance of clinical symptoms, in one case it was detected during a follow-up examination. All patients received anti-relapse therapy with drugs that penetrate the blood-brain barrier, two received molecular-directed therapy with ALK inhibitors, and only one patient received craniospinal irradiation and intrathecal administration of a chemotherapy drug.Two patients died as the disease progressed. One patient is alive at the time of the publication without disease progression, the follow-up time is 9 months from the diagnosis of relapse.Conclusions. Leptomenigial CNS lesion in relapse NB may be characterized by a non-specific clinical presentation requiring a differential diagnosis with the toxicity of therapy. Comprehensive therapeutic approach with chemotherapy, radiation therapy, and intrathecal administration of drugs is needed to improve the long-term survival of this subgroup of patients.

  • Open Access

    Results of treatment of patients with high and very high risk hepatoblastoma

    by R. A. Moiseenko, D. G. Akhaladze, A. V. Filin, M. Ya. Yadgarov, E. F. Kim, G. S. Rabaev, E. V. Feoktistova, N. N. Merkulov, A. V. Metelin, G. V. Tereshchenko, et al.

    Background. Hepatoblastoma (HB) is the most common malignant liver tumor in children aged 0–14 years. The introduction of intensive therapy based on alternating courses of cisplatin and carboplatin/doxorubicin, as well as dose-compression regimens of cisplatin administration, has significantly improved the prognosis in high-risk patients.The aim of the study – to assess the effectiveness of therapy in high-risk (HR) and very high-risk (VHR) patients with HB treated according to the International Group for Optimization of Therapy in Pediatric Liver Tumors (SIOPEL) protocols based on 2 major medical centers in the Russian Federation.Materials and methods. The study included patients with a verified diagnosis of HR and VHR HB, who received therapy at Dmitry Rogachev National Medical Research Center of the Pediatric Hematology, Oncology and Immunology and B.V. Petrovsky Russian Scientific Center of Surgery for the period 02.2012 to 07.2022 (125 months). The criteria of the SIOPEL group were used to stratify into risk groups. Until 2017, all patients were stratified into the HR group and received treatment according to the SIOPEL-4 protocol; since 2017, differentiated therapy has been carried out for patients in the HR group (SIOPEL-3 HR protocol) and VHR (SIOPEL-4 protocol). Since 2017, patients over 8 years of age have been stratified into VHR group. Survival was estimated using the Kaplan–Meier method. This study assessed overall survival (OS), event-free survival (EFS), and cumulative probability of death. Survival analysis was carried out as of 01.08.2023.Results. 49 patients with HR and VHR group HB aged 0 to 13 years were registered. The analysis included 47/49 (95.9 %) patients who received therapy according to the SIOPEL protocols. The median age at diagnosis was 24.9 months (range – 4.7–154.9). The male: female ratio was 1.47:1. Distribution by PRETEXT stage: PRETEXT II – 13 (27.6 %), PRETEXT III – 18 (38.3 %), PRETEXT IV – 16 (34.1 %) patients. The median α-fetoprotein level in patients with known exact values (n = 45) at the time of diagnosis was 182 431 (0.85–1 998 000) ng/ml. 24/47 (51 %) patients had initial lung metastases. The extent of delayed surgery: resection – 32 (68.1 %) patients, transplantation – 12 (25.5 %), without delayed surgery – 3 (6.4 %). Radicality of delayed surgery: R0 – 41/47 (87.2 %) patients, R1 – 3/47 (6.4 %), in 3/47 (6.4 %) patients the surgery wasn’t performed. Median follow-up 39.2 (2.5–129.2) months. Of the 47 patients included in the study, 37 (78.7 %) are alive, 10 (21.3 %) died (2/10 – surgical complications, 1/10 – infectious complications, 7/10 – progression of HB). Relapses/progressions were observed in 14/47 (29.8 %) patients, 7 (50 %) of whom died from disease progression. 3-year OS and EFS of the whole cohort (n = 47) were 80.1 ± 6.0 % and 64.9 ± 7.1 %. In the group of patients after liver transplantation (n = 12), 3-year OS and EFS were 73.3 ± 13.2 % and 64.2 ± 14.4%. The 3-year cumulative probability of death from the tumor was 16.7 ± 5.8 %. The 3-year cumulative probability of death from other causes was 7.2 ± 4.0 %. 3-year OS and EFS in the group of patients with distant metastases were 76.5 ± 9.4 % and 57.1 ± 10.3 %, in the group of patients without metastases 77.6 ± 8.8 % and 73.0 ± 9.4 %, respectively (p = 0,919 for OS; р = 0,440 for EFS).Conclusions. The data obtained in the study are consistent with the original studies of the SIOPEL group. The feasibility and effectiveness of incorporating liver transplantation into the treatment of patients with HB in the HR and VHR groups was confirmed.

  • Open Access

    Radiation therapy to metastatic sites among patients with high-risk neuroblastoma in first-line therapy

    by T. V. Shamanskaya, Yu. M. Voevodina, A. Yu. Usychkina, Yu. N. Likar, Ch. Kailash, M. M. Dunaykin, D. Yu. Kachanov, A. V. Nechesnyuk

    Relevance. Radiation therapy (RT) is one of the components of multimodal treatment among patients with high-risk neuroblastoma (NB), and in combination with surgical treatment is a mandatory element of local control of the primary tumor. At the same time, RT for metastatic sites persisting after completion of induction therapy is not a standard protocol treatment in primary patients with high-risk NB. The effect of RT on metastatic sites on improving long-term survival and reducing recurrence rates continues to be studied.Aim to the study – to investigate approaches to RT for single metastatic foci persisting after induction therapy among patients with NB highrisk group as part of the consolidation phase of first-line therapy.Materials and methods. The retrospective analysis included 11 patients with high-risk NB who underwent RT for metastatic foci as part of first-line therapy at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia from 01.2012 to 12.2023. Patients received therapy according to the modified protocol GPON-NB2004. The indication for RT was the persistence of a single metastatic site detected by 123I-metaiodobenzylguanidine scintigraphy or computed tomography/magnetic resonance imaging after completion of induction chemotherapy.Results. The median age was 31.9 months (range 9.4–128.6 months). All patients were initially with stage 4 disease (one patient had metastatic focus in the orbit without detection of the primary tumor). MYCN gene amplification was detected in 4/11 (36 %) cases. 10/11 (91 %) patients achieved а partial response after induction therapy. In all cases, only one metastatic focus was irradiated. 2/11 patients received radiation to both the primary tumor and metastatic focus.10/11 patients received RT to metastatic sites localized in skeletal bones, 1/11 – to a distant lymph node. Seven of 11 sites received 21 Gy in 14 fractions. The median follow-up was 40 months (range 13–97 months). Only 1 of 11 patients receiving metastatic site irradiation experienced relapse in an irradiated distant site 24 months later. The 3-year relapse-free survival and overall survival were 54 % and 80 % respectively.Conclusions. RT may be an effective method of local control in oligometastatic disease and in case of persisted single metastatic foci after induction chemotherapy in the treatment of high-risk NB. Additional large studies are needed to confirm the role of RT in improving survival with irradiation of metastatic sites.

  • Technical aspects of laparoscopic removal of neurogenic tumors of abdominal localization in children

    by Oncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology, D.G. Akhaladze, G.S. Rabayev, A.A. Krivonosov, I.V. Tverdov, N.A. Kriventsova, T.V. Shamanskaya, D.YU. Kachanov, N.S. Grachyov

    Progress in a modern pediatric oncological surgery, including neuroblastoma surgery, is characterized by increased role of the minimally-invasive approach. Authors represent standardized technical aspects of abdominal neuroblastoma laparoscopic resection. The purpose of this research was to systematize the technical aspects of laparoscopic resection for pediatric abdominal neuroblastoma, also in cases with Image-Defined Risk Factors (IDRF). Methods used: pre- and intraoperative data of 181 patients (85 (47%) males/96 (53%) females) of the median age of 14 [5-51] (1-209) months old with abdominal neuroblastoma who had received laparoscopic tumor resection at the National Scientific and Practical Center for Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev (Moscow, Russia) in Jan. 2018-Jan. 2024 were analyzed. Technical features of laparoscopic surgery procedure, also in cases with IDRF have been systematized as follows: patient position on the operating table, trocars placement, visualization of surgical field, dissection plan. Results: maximal tumor length was 3,6 [2,6-5] (0,7-12,6) cm, maximal tumor volume was 16,8 [4-40] (0,5-557) ml. IDRF were identified in 53 (29%) cases, wherein two and more IDRFs were in 19 (10%) patients. The surgical intervention duration was 100 [70-140] (35-725) minutes, intraoperative blood loss was 5 [5-18] (5-3600) ml, intraoperative transfusion was 0 [0-0] (0-890) ml. Intraoperative complications were observed in 6 (3%) patients, conversion was required in 7 (4%) cases. Complete tumor resection (98% to 100%) was achieved in 163 (90%) cases. Conclusion: the accumulated experience of minimally invasive surgery for neuroblastoma indicates the demand for reviewing of the current indications for these surgical procedures as well as a precise investigation of the effect of each IDRF on the difficulty and risk of surgery. In this Article Authors have described standardized technical features of abdominal neuroblastoma laparoscopic resection. These technical features are used in prospective clinical trial whilst the purpose of this research was to design the difficulty scoring system for such surgery (ClinicalTrials.gov ID NCT06296732).